Has Stephen Thomas received payments from drug or device companies?

Yes. Drug and device makers reported $293,859 in general payments to Stephen Thomas across 152 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Stephen Thomas did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Stephen Thomas come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Stephen Thomas

Infectious Disease · Syracuse, NYNPI 1154482339

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (46.6%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Pfizer at 51.3% of the total. Among infectious disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$293,859in general payments, 2019–2025

Across 152 payments — averaging $1933.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$151K
Sanofi Pasteur Inc.$56K
Sanofi US Services Inc.$30K
Merck$26K
Takeda Pharmaceuticals U.S.A., Inc.$22K
Modernatx, Inc.$7K
plus $1K from 2 others

$5,935,642in research payments, 2019–2025

Across 241 payments — averaging $24,629 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$5.8M
GSK$66K
Merck$25K

What the payments were for

Consulting fees$136,85347%
Speaking & faculty fees$73,58025%
Travel & lodging$80,61927%
Food & beverage$2,6531%
Education$130%
Gifts$200%
Entertainment$1230%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer(2 entities)	53	$150,667
Sanofi Pasteur Inc.	7	$56,169
Sanofi US Services Inc.	16	$29,769
Merck	27	$26,285
Takeda Pharmaceuticals U.S.A., Inc.	21	$22,451
Modernatx, Inc.	24	$7,210
Valneva USA, Inc.	2	$870
AstraZeneca	2	$438

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

COMIRNATY$79,734
NO PRODUCT DISCUSSED$29,559
PREVNAR - 13$11,290
PAXLOVID$7,541
V181$368
ELREXFIO$149
IXCHIQ$123

How this compares

$293,859 in reported general payments places this provider in the 95th percentile of 799 infectious disease providers in New York.

See all infectious disease providers in New York →

Other infectious disease in Syracuse

Timothy EndySyracuse$19K
Harish MoorjaniBriarcliff Manor$733K
Sorana Segal MaurerFlushing$598K
Sian JonesNew York$406K
Antonio UrbinaNew York$373K
David BekhorNew York$358K
Andre BrutusBrooklyn$303K
Glenn TurettFlushing$253K
Genovefa PapanicolaouNew York$209K
Abhay DhandValhalla$201K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →